University of Siena School of Medicine, Division of Psychiatry, Department of Neuroscience, Siena 53100, Italy.
Expert Opin Pharmacother. 2010 Jul;11(10):1727-40. doi: 10.1517/14656566.2010.490831.
It is very rare for patients with bipolar disorder to have a single episode of mania or depression over a lifetime and the vast majority of these individuals need long-term prophylactic/maintenance treatment. However, treatment nonadherence is a major issue for close to half of subjects with bipolar disorder who are prescribed medications. Risperidone long-acting injection (LAI) has proven efficacious for the maintenance phase of bipolar disorder and may mitigate the problem of nonadherence in the substantial group of patients for whom this is a significant concern.
This paper comprises a review and commentary regarding the use of risperidone LAI in bipolar disorder.
The reader will gain an understanding regarding the risks and benefits of risperidone LAI in bipolar disorder. We review the available evidence and discuss the strengths and weaknesses of published studies, providing an opinion about the clinical usefulness of risperidone LAI as well as suggestions for future research.
The use of risperidone LAI, through improved adherence, has the potential to ameliorate the course of bipolar disorder.
躁郁症患者一生中仅出现单次躁狂或抑郁发作的情况非常罕见，而绝大多数此类患者需要长期预防/维持治疗。然而，近一半的接受药物治疗的躁郁症患者存在治疗依从性差的问题。利培酮长效注射剂（LAI）已被证明对双相情感障碍的维持治疗有效，并且可能减轻对大量患者来说这是一个重大问题的不依从问题。
本文综述了利培酮 LAI 在双相情感障碍中的应用。
读者将了解利培酮 LAI 在双相情感障碍中的风险和益处。我们回顾了现有证据，并讨论了已发表研究的优缺点，对利培酮 LAI 的临床实用性提出了看法，并对未来的研究提出了建议。
通过提高依从性，使用利培酮 LAI 有可能改善双相情感障碍的病程。
